TY  - JOUR
T1  - SAfer cancer drug
AU  - Hampton T
Y1  - 2013/02/06
N1  - 10.1001/jama.2013.269
JO  - JAMA
SP  - 431
EP  - 431
VL  - 309
IS  - 5
N2  - 
In cancer cells, navitoclax targets BCL-2, a prosurvival protein (a molecule that helps the cancer cell evade programmed cell death). But navitoclax also inhibits BCL-2–like 1 (BCL-XL), which is a related factor required for the survival of platelets. Therefore, treatment with the drug often causes thrombocytopenia.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2013.269
UR  - http://dx.doi.org/10.1001/jama.2013.269
ER  -